Clinical and metabolic effects of rosiglitazone and metformin in non-obese women with polycystic ovary syndrome and metabolic disorders: a randomized controlled trial

Trial Profile

Clinical and metabolic effects of rosiglitazone and metformin in non-obese women with polycystic ovary syndrome and metabolic disorders: a randomized controlled trial

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Metformin (Primary) ; Rosiglitazone (Primary)
  • Indications Metabolic disorders; Polycystic ovary syndrome
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Mar 2016 Status changed from not yet recruiting to completed.
    • 03 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top